ELI LILLY AND COMPANY Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax of $9.70 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-20.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax · last filed 2018-02-20
- ELI LILLY AND COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2017-12-31 was $1.30M, a 7.14% decline year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2017-09-30 was $1.30M, a 0.00% change year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2017-06-30 was $5.80M, a 5700.00% increase year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2017-03-31 was $1.30M, a 0.00% change year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2017 was $9.70M, a 136.59% increase from fiscal 2016.
- ELI LILLY AND COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2016 was $4.10M.
- ELI LILLY AND COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2015 was -$14.60M.
- ELI LILLY AND COMPANY other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2014 was -$5.20M.
| Period end | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 3 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 3 month as first filed | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 6 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 6 month as first filed | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 9 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 9 month as first filed | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 12 month |
|---|---|---|---|---|---|---|---|
| 2017-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $2.60M derived: sum of 2 quarters · filed 2018-02-20 | $8.40M derived: sum of 3 quarters · filed 2018-02-20 | $9.70M 10-K · filed 2018-02-20 | |||
| 2017-09-30 | $1.30M 10-Q · filed 2017-10-27 | $7.10M derived: sum of 2 quarters · filed 2017-10-27 | $8.40M 10-Q · filed 2017-10-27 | $9.80M derived: sum of 4 quarters · filed 2018-02-20 | |||
| 2017-06-30 | $5.80M 10-Q · filed 2017-07-28 | $7.10M 10-Q · filed 2017-07-28 | $8.50M derived: sum of 3 quarters · filed 2018-02-20 | $9.80M derived: sum of 4 quarters · filed 2018-02-20 | |||
| 2017-03-31 | $1.30M 10-Q · filed 2017-05-01 | $2.70M derived: sum of 2 quarters · filed 2018-02-20 | $4.00M derived: sum of 3 quarters · filed 2018-02-20 | $4.10M derived: sum of 4 quarters · filed 2018-02-20 | |||
| 2016-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $2.70M derived: sum of 2 quarters · filed 2018-02-20 | $2.80M derived: sum of 3 quarters · filed 2018-02-20 | $4.10M 10-K · filed 2018-02-20 | |||
| 2016-09-30 | $1.30M 10-Q · filed 2017-10-27 | $1.40M derived: sum of 2 quarters · filed 2017-10-27 | $2.70M 10-Q · filed 2017-10-27 | -$27.80M derived: sum of 4 quarters · filed 2018-02-20 | |||
| 2016-06-30 | $100.00K 10-Q · filed 2017-07-28 | $1.40M 10-Q · filed 2017-07-28 | -$29.10M derived: sum of 3 quarters · filed 2018-02-20 | -$30.40M derived: sum of 4 quarters · filed 2018-02-20 | |||
| 2016-03-31 | $1.30M 10-Q · filed 2017-05-01 | -$29.20M derived: sum of 2 quarters · filed 2018-02-20 | -$30.50M derived: sum of 3 quarters · filed 2018-02-20 | -$29.20M derived: sum of 4 quarters · filed 2018-02-20 | |||
| 2015-12-31 | -$30.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | -$31.80M derived: sum of 2 quarters · filed 2018-02-20 | -$30.50M derived: sum of 3 quarters · filed 2018-02-20 | -$14.60M 10-K · filed 2018-02-20 | |||
| 2015-09-30 | -$1.30M 10-Q · filed 2016-10-28 | $0.00 derived: sum of 2 quarters · filed 2016-10-28 | $15.90M 10-Q · filed 2016-10-28 | -$3.80M derived: sum of 4 quarters · filed 2017-02-21 | |||
| 2015-06-30 | $1.30M 10-Q · filed 2016-07-28 | -$1.30M 10-Q · filed 2015-07-30 | -$17.20M 10-Q · filed 2016-07-28 | $17.20M 10-Q · filed 2015-07-30 | -$2.50M derived: sum of 3 quarters · filed 2017-02-21 | $8.20M derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-03-31 | -$18.50M 10-Q · filed 2016-04-29 | -$3.80M derived: sum of 2 quarters · filed 2017-02-21 | $6.90M derived: sum of 3 quarters · filed 2017-02-21 | -$1.30M derived: sum of 4 quarters · filed 2017-02-21 | |||
| 2014-12-31 | $14.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $25.40M derived: sum of 2 quarters · filed 2017-02-21 | $17.20M derived: sum of 3 quarters · filed 2017-02-21 | -$5.20M 10-K · filed 2017-02-21 | |||
| 2014-09-30 | $10.70M 10-Q · filed 2015-10-30 | -$10.70M 10-Q · filed 2014-10-29 | $2.50M derived: sum of 2 quarters · filed 2015-10-30 | -$19.90M 10-Q · filed 2015-10-30 | $19.90M 10-Q · filed 2014-10-29 | -$5.60M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-06-30 | -$8.20M 10-Q · filed 2015-07-30 | $8.20M 10-Q · filed 2014-07-28 | -$30.60M 10-Q · filed 2015-07-30 | $30.60M 10-Q · filed 2014-07-28 | -$16.30M derived: sum of 3 quarters · filed 2016-02-19 | -$27.70M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-03-31 | $22.40M 10-Q · filed 2015-04-30 | -$8.10M derived: sum of 2 quarters · filed 2016-02-19 | -$19.50M derived: sum of 3 quarters · filed 2016-02-19 | -$21.80M derived: sum of 4 quarters · filed 2016-02-19 | |||
| 2013-12-31 | -$30.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | -$41.90M derived: sum of 2 quarters · filed 2016-02-19 | -$44.20M derived: sum of 3 quarters · filed 2016-02-19 | -$43.20M 10-K · filed 2016-02-19 | |||
| 2013-09-30 | -$11.40M 10-Q · filed 2014-10-29 | -$13.70M derived: sum of 2 quarters · filed 2014-10-29 | -$12.70M 10-Q · filed 2014-10-29 | ||||
| 2013-06-30 | -$2.30M 10-Q · filed 2014-07-28 | -$1.30M 10-Q · filed 2014-07-28 | |||||
| 2013-03-31 | $700.00K 10-Q · filed 2014-04-28 | ||||||
| 2012-12-31 | $2.80M 10-K · filed 2015-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |